Briacell Therapeutics CORP. (BCTXZ) — SEC Filings

Q: What are the key financial highlights for Briacell Therapeutics CORP.?

Key financial highlights for Briacell Therapeutics CORP. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Briacell Therapeutics CORP.?

Key executives at Briacell Therapeutics CORP. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Briacell Therapeutics CORP. stock?

Risk factors for Briacell Therapeutics CORP. (BCTXZ) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Briacell Therapeutics CORP.?

Forward-looking statements and predictions from Briacell Therapeutics CORP. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Briacell Therapeutics CORP.. Recent 8-K filing on Dec 29, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Briacell Therapeutics CORP. on SEC EDGAR

Overview

Briacell Therapeutics CORP. (BCTXZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: BriaCell Therapeutics Corp. filed an 8-K on December 29, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and operates in the Pharmaceutical Preparations sector.

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 36 neutral, 5 mixed. The dominant filing sentiment for Briacell Therapeutics CORP. is neutral.

Filing Type Overview

Briacell Therapeutics CORP. (BCTXZ) has filed 25 8-K, 3 S-1, 5 10-Q, 2 10-K, 3 S-1/A, 2 DEF 14A, 4 SC 13D/A, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (46)

BriaCell Therapeutics Files 8-K — 8-K · Dec 29, 2025 Risk: low
BriaCell Therapeutics Corp. filed an 8-K on December 29, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as A
BriaCell Launches Unit Offering Amidst Positive Clinical Trial Momentum — S-1 · Dec 23, 2025 Risk: high
BriaCell Therapeutics Corp. (BCTXZ) is conducting a best efforts offering of up to 2,793,296 Common Units, each consisting of one common share and one warrant,
BriaCell's Q1 Loss Widens 42% on Soaring R&D Costs — 10-Q · Dec 11, 2025 Risk: high
BriaCell Therapeutics Corp. (BCTXZ) reported a significant increase in net loss for the three months ended October 31, 2025, reaching $8,278,328, up from $5,829
8-K Filing — 8-K · Dec 1, 2025
BriaCell's Immunotherapy Shows Promise in Metastatic Breast Cancer — 10-K · Oct 16, 2025 Risk: high
BriaCell Therapeutics Corp. (BCTXZ) is a clinical-stage biotechnology company focused on novel immunotherapies for cancer. The company is advancing its Bria-IMT
BriaCell Therapeutics Corp. Files 8-K — 8-K · Aug 26, 2025 Risk: medium
BriaCell Therapeutics Corp. filed an 8-K on August 26, 2025, reporting an event that occurred on August 21, 2025. The filing indicates a change in the company's
BriaCell Therapeutics Corp. Enters Material Definitive Agreement — 8-K · Jul 16, 2025 Risk: medium
BriaCell Therapeutics Corp. announced on July 15, 2025, that it entered into a material definitive agreement. The company, formerly known as Ansell Capital Corp
BriaCell Amends S-1 for Continuous Offering, Eyes Public Capital — S-1/A · Jul 10, 2025 Risk: high
BriaCell Therapeutics Corp. filed an S-1/A on July 10, 2025, as Amendment No. 2 to its Form S-1 Registration Statement, indicating a proposed sale of securities
BriaCell Amends S-1, Signals Continuous Offering Strategy — S-1/A · Jul 9, 2025 Risk: high
BriaCell Therapeutics Corp. (BCTXZ) filed an S-1/A on July 9, 2025, indicating an amendment to its registration statement for a proposed public sale of securiti
BriaCell Files S-1 for Continuous Offering, Signaling Capital Raise — S-1 · Jul 8, 2025 Risk: high
BriaCell Therapeutics Corp. (BCTXZ) filed an S-1 registration statement on July 8, 2025, for a proposed sale of securities on a delayed or continuous basis, ind
BriaCell Therapeutics Files 8-K Report — 8-K · Jun 18, 2025 Risk: low
On June 16, 2025, BriaCell Therapeutics Corp. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits
BriaCell's Q3 Loss Widens Amid Increased R&D Spend — 10-Q · Jun 16, 2025 Risk: high
BriaCell Therapeutics Corp. reported no revenue for the three and nine months ended April 30, 2025, consistent with its clinical-stage biotechnology status. The
BriaCell Therapeutics Corp. Signs Material Definitive Agreement — 8-K · Apr 28, 2025 Risk: medium
BriaCell Therapeutics Corp. announced on April 24, 2025, that it entered into a material definitive agreement. The company, previously known as Ansell Capital C
BriaCell Therapeutics Corp. Files S-1/A Amendment — S-1/A · Apr 23, 2025 Risk: medium
BriaCell Therapeutics Corp. filed an S-1/A amendment on April 23, 2025, for its registration statement. The company, formerly known as Ansell Capital Corp. unti
BriaCell Therapeutics Files S-1 for Potential Offering — S-1 · Apr 22, 2025 Risk: medium
BriaCell Therapeutics Corp. filed an S-1 registration statement on April 22, 2025, for an unspecified offering. The company, formerly known as Ansell Capital Co
BriaCell Therapeutics Files 8-K — 8-K · Mar 12, 2025 Risk: low
BriaCell Therapeutics Corp. filed an 8-K on March 12, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
BriaCell to Acquire Inovio Pharmaceuticals for $100M — 8-K · Feb 13, 2025 Risk: medium
BriaCell Therapeutics Corp. announced on February 12, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Inovio Pharmace
BriaCell Therapeutics Holds Security Holder Vote — 8-K · Feb 6, 2025 Risk: low
BriaCell Therapeutics Corp. filed an 8-K on February 6, 2025, reporting on a meeting of security holders held on February 5, 2025. The filing indicates that mat
BriaCell Therapeutics Corp. Files 8-K — 8-K · Feb 5, 2025 Risk: medium
BriaCell Therapeutics Corp. announced on February 3, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales
BriaCell Therapeutics to Acquire Inovio Pharmaceuticals — 8-K · Jan 28, 2025 Risk: medium
BriaCell Therapeutics Corp. announced on January 24, 2025, that it has entered into a definitive agreement to acquire all of the outstanding shares of Inovio Ph
BriaCell Therapeutics Corp. Files 8-K — 8-K · Jan 3, 2025 Risk: low
BriaCell Therapeutics Corp. filed an 8-K on January 3, 2025, reporting other events and financial statements. The company, previously known as Ansell Capital Co
BriaCell Therapeutics Files Definitive Proxy Statement — DEF 14A · Dec 17, 2024 Risk: low
BriaCell Therapeutics Corp. filed a definitive proxy statement (DEF 14A) on December 17, 2024. This filing is related to the company's annual meeting and is not
BriaCell Therapeutics Files 10-Q for Q1 2025 — 10-Q · Dec 16, 2024 Risk: medium
BriaCell Therapeutics Corp. filed a 10-Q for the period ending October 31, 2024. The company, formerly known as Ansell Capital Corp., reported financial data fo
BriaCell Therapeutics Corp. Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 13, 2024 Risk: medium
On December 11, 2024, BriaCell Therapeutics Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securi
L5 Capital Inc. Amends BriaCell Therapeutics Stake — SC 13D/A · Dec 12, 2024 Risk: medium
L5 Capital Inc. filed an amendment (No. 4) to its Schedule 13D on December 12, 2024, regarding its holdings in BriaCell Therapeutics Corp. The filing indicates
L5 Capital Inc. Amends BriaCell Therapeutics Stake — SC 13D/A · Dec 10, 2024 Risk: medium
L5 Capital Inc. filed an amendment (No. 3) to its Schedule 13D on December 10, 2024, regarding its holdings in BriaCell Therapeutics Corp. The filing indicates
L5 Capital Inc. Amends BriaCell Therapeutics Stake — SC 13D/A · Dec 5, 2024 Risk: medium
L5 Capital Inc. filed an amendment (No. 2) to its Schedule 13D on December 5, 2024, regarding its holdings in BriaCell Therapeutics Corp. The filing indicates a
BriaCell Therapeutics Names New Directors and CMO — 8-K · Nov 25, 2024 Risk: medium
BriaCell Therapeutics Corp. announced on November 23, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the compan
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
BriaCell Therapeutics Files 8-K — 8-K · Nov 1, 2024 Risk: low
BriaCell Therapeutics Corp. filed an 8-K on November 1, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, former
BriaCell Therapeutics Files 2024 10-K — 10-K · Oct 29, 2024 Risk: medium
BriaCell Therapeutics Corp. filed its 10-K for the fiscal year ending July 31, 2024, reporting on its financial condition and business operations. The company,
BriaCell Therapeutics Corp. Files 8-K: Material Definitive Agreement — 8-K · Oct 2, 2024 Risk: medium
On October 1, 2024, BriaCell Therapeutics Corp. entered into a material definitive agreement, the details of which are not fully disclosed in this filing but ar
BriaCell Therapeutics Corp. Files 8-K — 8-K · Oct 1, 2024 Risk: low
BriaCell Therapeutics Corp. filed an 8-K on October 1, 2024, reporting other events and financial statements. The company, formerly known as Ansell Capital Corp
SC 13G Filing — SC 13G · Sep 16, 2024
BriaCell Therapeutics Corp. Files 8-K — 8-K · Sep 12, 2024 Risk: medium
BriaCell Therapeutics Corp. announced on September 11, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sal
BriaCell Therapeutics Files 8-K — 8-K · Sep 11, 2024 Risk: low
BriaCell Therapeutics Corp. filed an 8-K on September 11, 2024, reporting other events and financial statements as of September 9, 2024. The company, formerly k
BriaCell Therapeutics Faces Delisting Notice — 8-K · Aug 23, 2024 Risk: high
BriaCell Therapeutics Corp. filed an 8-K on August 22, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was for
BriaCell Therapeutics Files 8-K — 8-K · Jul 18, 2024 Risk: low
On July 18, 2024, BriaCell Therapeutics Corp. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
BriaCell Therapeutics Faces Delisting Concerns — 8-K · Jul 5, 2024 Risk: high
BriaCell Therapeutics Corp. filed an 8-K on July 5, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The compan
BriaCell Therapeutics Files Q3 2024 10-Q — 10-Q · Jun 14, 2024 Risk: medium
BriaCell Therapeutics Corp. filed its 10-Q for the period ending April 30, 2024. The company reported financial results and operational updates. Key financial f
L5 Capital Inc. Amends BriaCell Therapeutics Stake Filing — SC 13D/A · May 24, 2024 Risk: medium
L5 Capital Inc. filed an amendment (No. 1) to its Schedule 13D on May 24, 2024, regarding its holdings in BriaCell Therapeutics Corp. The filing indicates a cha
BriaCell Therapeutics Corp. Files 8-K — 8-K · May 17, 2024 Risk: medium
BriaCell Therapeutics Corp. announced on May 14, 2024, that it entered into a material definitive agreement. The company also reported other events and filed fi
BriaCell Therapeutics to Acquire Lexo, Inc. for $10M — 8-K · Apr 2, 2024 Risk: medium
BriaCell Therapeutics Corp. announced on April 1, 2024, that it has entered into a definitive agreement to acquire all of the outstanding shares of Lexo, Inc. f
BriaCell Therapeutics Corp. Files 10-Q for Period Ending January 31, 2024 — 10-Q · Mar 18, 2024 Risk:
BriaCell Therapeutics Corp. (BCTXZ) filed a Quarterly Report (10-Q) with the SEC on March 18, 2024. BriaCell Therapeutics Corp. filed a 10-Q for the period endi
BriaCell Files 8-K on Shareholder Vote Matters — 8-K · Jan 31, 2024
BriaCell Therapeutics Corp. filed an 8-K on January 31, 2024, reporting an event on January 30, 2024, related to the submission of matters to a vote of security
BriaCell Therapeutics Corp. Announces Annual General Meeting on January 30, 2024 — DEF 14A · Jan 9, 2024 Risk: low
BriaCell Therapeutics Corp. (BCTXZ) filed a Proxy Statement (DEF 14A) with the SEC on January 9, 2024. BriaCell Therapeutics Corp. will hold its Annual General

Risk Profile

Risk Assessment: Of BCTXZ's 41 recent filings, 9 were flagged as high-risk, 21 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Briacell Therapeutics CORP.'s most recent 10-Q filing (Dec 11, 2025):

Revenue: $0
Net Income: $ -8,278,328
EPS: $ -4.35
Debt-to-Equity: N/A
Cash Position: $ 2,714,012
Operating Margin: N/A
Total Assets: $ 13,075,050
Total Debt: $ 406,873

Key Executives

Dr. William V. Williams
Gregory Sichenzia, Esq.
Avital Perlman, Esq.
Virgil Hlus, Esq.
Andrew Stewart, Esq.
Chief Executive Officer
Gregory Sichenzia
Avital Perlman
Marc Lustig
Dr. Steven A. Rosenberg
Mr. Jeffrey S. Hackman

Industry Context

BriaCell operates in the highly competitive oncology immunotherapy market, focusing on novel approaches to stimulate the immune system against cancer. The market is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Key trends include the development of personalized medicine, combination therapies, and advancements in understanding the tumor microenvironment.

Top Tags

corporate-event (8) · Biotechnology (7) · financials (6) · material-agreement (6) · sec-filing (5) · biotech (5) · filing (4) · Emerging Growth Company (4) · Oncology (4) · disclosure (4)

Key Numbers

Maximum Common Units offered: 2,793,296 — Each unit consists of one common share and one warrant
Maximum Pre-funded Units offered: 2,793,296 — Each unit consists of one pre-funded warrant and one warrant
Assumed public offering price per Common Unit: $8.95 — Based on Nasdaq closing price of common shares on December 19, 2025
Exercise price per Warrant: $11.1875 — Equal to 125% of the assumed public offering price of one Common Unit
Exercise price per Pre-funded Warrant: $0.001 — Significantly lower than common share exercise price
Last reported sale price of common shares on Nasdaq: $9.73 — As of December 22, 2025
Median overall survival in BriaCell's Phase 2 study: 13.4 months — For metastatic breast cancer patients, compared to 6.7-9.8 months in literature
Small Business Innovation Research (SBIR) grant: $2.0 million — Awarded by U.S. National Cancer Institute (NCI) for Bria-PROS+™
Clinical sites enrolling patients: 79 — Across 23 U.S. states for the Phase 3 study of Bria-IMT™
Offering termination date: March 15, 2026 — Unless completed sooner or terminated earlier by the company
Net loss for the period: $8,278,328 — Increased from $5,829,276 in 2024, a 42% increase
Research and development expenses: $6,683,643 — Increased from $3,665,341 in 2024, a 82% increase
Cash and cash equivalents: $2,714,012 — Decreased from $10,493,808 on July 31, 2025
Negative cash flow from operating activities: $7,704,796 — For the three months ended October 31, 2025
Accumulated deficit: $119,953,129 — As of October 31, 2025

Related Companies

BCTX · BCT · BCTXW · INO

Frequently Asked Questions

What are the latest SEC filings for Briacell Therapeutics CORP. (BCTXZ)?

Briacell Therapeutics CORP. has 46 recent SEC filings from Jan 2024 to Dec 2025, including 25 8-K, 5 10-Q, 4 SC 13D/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BCTXZ filings?

Across 46 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 36 neutral, 5 mixed. The dominant sentiment is neutral.

Where can I find Briacell Therapeutics CORP. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Briacell Therapeutics CORP. (BCTXZ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Briacell Therapeutics CORP.?

Key financial highlights from Briacell Therapeutics CORP.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BCTXZ?

The investment thesis for BCTXZ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Briacell Therapeutics CORP.?

Key executives identified across Briacell Therapeutics CORP.'s filings include Dr. William V. Williams, Gregory Sichenzia, Esq., Avital Perlman, Esq., Virgil Hlus, Esq., Andrew Stewart, Esq. and 6 others.

What are the main risk factors for Briacell Therapeutics CORP. stock?

Of BCTXZ's 41 assessed filings, 9 were flagged high-risk, 21 medium-risk, and 11 low-risk.

What are recent predictions and forward guidance from Briacell Therapeutics CORP.?

Forward guidance and predictions for Briacell Therapeutics CORP. are extracted from SEC filings as they are enriched.